MS Bio was listed on the KOSDAQ market on the 22nd. The company, which develops medical products based on human tissue and biomaterials, showed strong momentum from its first day of trading. As of 9 a.m. on the 22nd, the stock price stood at 15,740 won, up 101.79% from the offering price, marking a 'double.'

The offering price was finalized at 7,800 won, the top of the desired range (6,800–7,800 won). The company recorded a high competition ratio of 1,096.56 to 1 in demand forecasting for institutional investors. The total number of shares offered is 4 million, and the offering amount based on the finalized price is 31.2 billion won.

The public subscription for retail investors took place from October 12 to 13, with KB Securities as the underwriter. The number of shares allocated to general subscribers was presented at 1 million to 1.2 million shares. The allocation announcement and payment/refund procedures were scheduled for October 15, with the listing date set for October 22.

■ MYDERM is the Core Product

MS Bio is a company pursuing the commercialization of medical products utilizing human tissue and biomaterials. While expanding its existing human tissue-based product business, the company is also developing next-generation tissue regeneration materials and convergent medical devices based on its accumulated tissue engineering technology.

Its flagship product, MYDERM, is an acellular dermal matrix product derived from human tissue. The company produces the product through donor screening and tissue processing, and says it has a quality management system that complies with the relevant regulations of the Ministry of Food and Drug Safety and the American Association of Tissue Banks (AATB).

MYDERM is a product with an acellular purification process applied, featuring a Ready To Use (RTU) format that can be used immediately without a separate hydration process. Since it does not require hydration before use, it is a product designed with convenience of use in clinical settings in mind. In addition, through specialized purification and processing technology, the company minimizes the fatty components of skin tissue and focuses on reducing DNA content, which can cause immune responses and transplant rejection, through the decellularization process. The company presents this process as a core technology for securing product safety and quality.

■ Business Expansion into Tissue Regeneration and Drug Delivery Convergent Devices

MS Bio plans to expand its existing business structure, centered on human tissue implants, into the medical device field combining tissue regeneration and drug delivery functions. In research and development, the company is pursuing convergent medical devices loaded with drugs such as antibiotics using collagen 3D scaffolds, as well as the development of next-generation tissue regeneration materials.

The collagen 3D scaffold is a three-dimensional support structure designed to support the growth and regeneration of cells and tissues, and is a material used in the field of tissue engineering. Drug-loaded convergent medical devices are also one of the new development areas the company is pursuing, with a plan to expand the application scope of medical products by combining drug delivery functions with its existing biomaterial technology.

Overseas business expansion is also included in its mid- to long-term growth plan. MS Bio is pursuing entry into the global market beyond the domestic market, and plans to expand its production and sales base through the establishment of amniotic membrane lens production facilities in the United States and other overseas regions. Through this, the company aims to broaden its business areas from research and development of medical products using human tissue and biomaterials to production and global commercialization.

■ Whether Results Will Translate into Revenue Remains to Be Seen

However, the next-generation medical device development and overseas production facility construction the company is pursuing are part of its future business plans. Whether R&D results and overseas business expansion will actually translate into revenue and profitability improvements must be confirmed through subsequent business progress. After listing, the expansion of the existing human tissue-based product business, development of new convergent medical devices, and establishment of overseas production and sales bases are expected to be key areas of interest.

Attention is also focused on what kind of first-day trading performance MS Bio, which recorded a high competition ratio in institutional demand forecasting and finalized its offering price at the top of the desired range, will deliver on the KOSDAQ market on the 22nd. However, a high institutional demand forecasting competition ratio does not guarantee a rise in the stock price on listing day, and the actual trading price is determined by the supply and demand of buying and selling in the market.

[This article is intended to provide information for investment reference and does not recommend the purchase or sale of any specific stock. It may vary depending on market conditions. Investment decisions and the responsibility for them rest with the investor. AI provided some assistance.]